Medicare to Offer Weight Loss Drugs to Eligible Beneficiaries Starting July

Medicare is set to allow coverage for popular weight loss medications under a new voluntary program, benefiting eligible enrollees who will pay only $50 a month. This initiative, named BALANCE, aims to improve health outcomes for individuals with obesity and related chronic conditions. Starting in July 2026, Medicare beneficiaries can access GLP-1 medications, with an estimated 10% of enrollees qualifying for this expanded access. The program is part of a broader effort to democratize access to essential health treatments, with price negotiations expected to keep costs manageable for both patients and taxpayers. The initiative highlights the importance of addressing obesity as a chronic disease, which affects over 70% of U.S. adults.

Key Details: • Eligible Medicare enrollees will pay $50 per month for GLP-1 medications. • Expanded access begins in July 2026, with a demonstration program running until December 2031. • Approximately 10% of Medicare enrollees are expected to qualify for this program. • State Medicaid agencies can join the model starting May 2026.